# US 2026/0098061 A1 · Epha2-binding pending peptide and composition comprising same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098061 A1
- Document ID: US20260098061A1
- Status: Published application
- Kind: A1
- Application number: 19/115,394
- Filed: 2023-09-28
- Published: 2026-04-09
- Earliest claimed: 2022-09-29
- Assignees: PeptiDream Inc.
- Applicants: PeptiDream Inc.
- Inventors: Takanori Aoki; Takeru Ehara; Sora Enya; Makoto Jitsuoka; Kouki Morimoto; Shunichi Nakano; Takayuki Nagasawa; Masaki Ohuchi; Hayato Yanagida; Zaid Amso; Rongjun He; Derek Cole
- Web page: https://patentgrep.com/patent/US20260098061A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- C07K 5/06034: {the side chain containing 2 to 4 carbon atoms}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present technology generally relates to peptides that bind to the Eph receptor A2 (EphA2), to peptides that bind to the EphA2, and to compositions comprising such peptides.

## Claims

### Claim 1

A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide comprises an amino acid sequence including deletion, substitution, and/or addition of one or several (e.g., 1-6) amino acids in the amino acid sequence of SEQ ID NO: 1:
(SEQ ID NO: 1)
da-MeF-N-L-Hgl-MeF-W1Me-V-W1Me-T-E-C
or a pharmaceutically acceptable salt thereof, wherein the (cyclic) peptide consists of 10 to 12 amino acid residues.

### Claim 2 (depends on 1)

The (cyclic) peptide of claim 1, wherein 1-5 amino acids selected the group consisting of the 3rd N, 4th L, 6th MeF, 10th T and 11th E of SEQ ID NO: 1, is/are deleted, optionally without additional addition and/or substitution.

### Claim 3 (depends on 1, 2)

The (cyclic) peptide of claim 1 or 2, wherein one to several (e.g., 1, 2, 3, 4 or 5) amino acids are added.

### Claim 4 (depends on 1, 2, 3)

The (cyclic) peptide of any one of claims 1 to 3, wherein one or more amino acid residues selected from the 2nd MeF, 6th MeF, 8th V and 11th E are substituted.

### Claim 5 (depends on 1, 2, 3, 4)

The (cyclic) peptide of any one of claims 1 to 4, wherein the peptide comprises an amino acid sequence with deletion of 2 or less amino acids in the amino acid SEQ ID NO: 1, optionally without additional addition and/or substitution.

### Claim 6 (depends on 5)

The (cyclic) peptide of claim 5, wherein 1-2 amino acids selected from the group consisting of the 10th T and 11th E of SEQ ID NO: 1 is/are deleted, optionally without additional addition and/or substitution.

### Claim 7

A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide comprises an amino acid sequence of Formula (I), or a pharmaceutically acceptable salt thereof,
wherein,
X1 is an amino acid;
X2 is an amino acid comprising an aromatic ring, an N-methylated amino acid thereof, or a variant thereof;
X3 is a hydrophilic amino acid (e.g. N, Q, Cit, K or a variant thereof), glycine (G), Alanine (A) or a variant thereof (e.g., da, 2-Aminoisobutyric acid (Aib);
X4 is a hydrophobic amino acid (e.g., leucine (L)), a hydrophilic amino acid (e.g., citrulline (Cit), or a variant thereof;
X5 is a hydrophilic amino acid, or a variant thereof;
X6 is a hydrophilic amino acid, an amino acid comprising an aromatic ring, or an N-methylated amino acid thereof;
X7 is an amino acid comprising an aromatic ring (e.g., W, F, or a variant thereof);
X8 is a hydrophobic amino acid, a hydrophilic amino acid, an N-methylated amino acid, or a variant thereof;
X9 is an amino acid comprising an aromatic ring (e.g., W or a variant thereof);
X10 is absent or a hydrophilic amino acid (e.g., Threonine (T) or a variant thereof);
X11 is absent or a hydrophilic amino acid; and
X12 is cysteine (C) or a variant thereof.

### Claim 8 (depends on 7)

The (cyclic) peptide of claim 7, wherein X3 is a hydrophilic amino acid.

### Claim 9 (depends on 8)

The (cyclic) peptide of claim 8, wherein X3 is an amino acid comprising an electrically charged side chain (e.g., K or a variant thereof), an amino acid comprising a polar uncharged side chain (e.g., Q, Cit, N, or a variant thereof), or G, A or variant thereof.

### Claim 10 (depends on 7, 8, 9)

The (cyclic) peptide of any one of claims 7-9, wherein X4 is a hydrophobic amino acid.

### Claim 11 (depends on 10)

The (cyclic) peptide of claim 10, wherein X4 is an amino acid comprising a hydrophobic side chain (e.g., L), an amino acid comprising a polar uncharged side chain (e.g., Cit or a variant thereof).

### Claim 12 (depends on 7, 8, 9, 10, 11)

The (cyclic) peptide of any one of claims 7-11, wherein X5 is a hydrophilic amino acid.

### Claim 13 (depends on 12)

The (cyclic) peptide of claim 12, wherein X5 is an amino acid comprising an electrically charged side chain (e.g., E, Hgl, D, or a variant thereof), or an amino acid comprising a polar uncharged side chain (e.g., Q, Cit, Hgn, N, or a variant thereof).

### Claim 14 (depends on 7, 8, 9, 10, 11, 12, 13)

The (cyclic) peptide of any one of claims 7-13, wherein X6 is a hydrophilic amino acid.

### Claim 15 (depends on 14)

The (cyclic) peptide of claim 14, wherein X6 is an amino acid comprising an electrically charged side chain (e.g., E, Hgl, D, or a variant thereof), or an amino acid comprising a polar uncharged side chain (e.g., Q, Cit, Hgn, N, or variant).

### Claim 16 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15)

The (cyclic) peptide of any one of claims 7-15, wherein X11 is a hydrophilic amino acid.

### Claim 17 (depends on 16)

The (cyclic) peptide of claim 16, wherein X11 is an amino acid comprising an electrically charged side chain (e.g., E, Hgl, D, R, hArg, K or a variant thereof), or an amino acid comprising a polar uncharged side chain (e.g., Q, Cit, Hgn, N, or a variant thereof).

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The (cyclic) peptide of any one of claims 1-17, wherein the peptide has an amino acid sequence of Formula (I), or a pharmaceutically acceptable salt thereof,
X1 is an amino acid;
X2 is F, or a variant thereof that substitutes the unsubstituted phenyl ring of F with:
(i) a phenyl ring substituted by 1 or 2 substituents each independently selected from —OH, —CN, —C1-3 alkyl (e.g., —CH3), or
(ii) a 6-membered heteroaryl ring optionally substituted by 1 or 2 substituents each independently selected from —OH, —CN, —C1-3 alkyl (e.g., —CH3),
wherein the F or the structural variant thereof is optionally N-methylated;
X3 is a hydrophilic amino acid (e.g. N, Q, Cit, K or a variant thereof), G, Alb, Hgn, Ala, or a variant thereof (e.g., da);
X4 is a hydrophobic amino acid (e.g., an amino acid having 4 or more carbon atoms in a side chain comprising a linear, branched, or cyclic carbon chain), and wherein X4 is optionally N-methylated (e.g., Cit or a variant thereof);
X5 is an amino acid (e.g., a hydrophilic amino acid; Dab, Dap, R, E or a variant thereof, or an amino acid with a functional side chain (e.g., not glycine);
X6 is an N-methylated amino acid thereof;
X7 is a W, Y, or a variant thereof (e.g., an amino acid having either a 6-membered aryl or heteroaryl, or a 9- or 10-membered bi-cyclic aryl or heteroaryl linked to the alpha-carbon through a carbon (e.g., a methylene group), wherein the 6-, 9-, and 10-membered heteroaryl has one heteroatom (e.g., N), and wherein the 6-, 9-, and 10-membered aryl or heteroaryl is optionally substituted by 1 or 2 substituents independently selected from —CH3, -ethyl, —Cl, and —F);
X8 is an amino acid with —H on the alpha-amino group;
X9 is W or Y or a variant thereof; (e.g., W or a variant thereof);
X10 is absent, or a polar amino acid (e.g., T or a variant thereof);
X11 is absent, or an amino acid (e.g., a hydrophilic amino acid; Dab, Dap, R, E or a variant thereof; or an amino acid with a functional side chain (e.g., not glycine); and
X12 is C or a variant thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The (cyclic) peptide of any one of claims 1 to 18, wherein the peptide has an amino acid sequence of Formula (Ia), or a pharmaceutically acceptable salt thereof,
wherein,
X1 is an amino acid (e.g., D-amino acid);
X2 is an amino acid comprising an aromatic ring, an N-methylated amino acid thereof, or a variant thereof;
X3 is a hydrophilic amino acid (e.g., N, Q, Cit, K or a variant thereof), G, A, or a variant thereof (e.g., da, Aib);
X4 is a hydrophobic amino acid, or a hydrophilic amino acid (e.g., Cit or a variant thereof);
X5 is a hydrophilic amino acid (e.g., Dab, Dap, R, E, Q, D, K), or a variant thereof);
X6 is a hydrophilic amino acid, an amino acid comprising an aromatic ring (e.g., W, or F, or a variant thereof), or an N-methylated amino acid thereof;
X7 is an amino acid comprising an aromatic ring (e.g., W, F, or a variant thereof);
X8 is a hydrophobic amino acid, a hydrophilic amino acid, or an N-methylated amino acid;
X9 is an amino acid comprising an aromatic ring (e.g., W, For a variant thereof); and
X12 is C or a variant thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The (cyclic) peptide of any one of claims 1 to 18, wherein the peptide has an amino acid sequence according to Formula (I), or a pharmaceutically acceptable salt thereof,
wherein,
X1 is an amino acid (e.g., D-amino acid);
X2 is an amino acid comprising an aromatic ring, an N-methylated amino acid thereof, or a variant thereof;
X3 is a hydrophilic amino acid (e.g., N, Q, Cit, K or a variant thereof), G, A, or a variant thereof (e.g., da, Aib);
X4 is a hydrophobic amino acid, or a hydrophilic amino acid (e.g., Cit or a variant thereof);
X5 is a hydrophilic amino acid (e.g., Dab, Dap, R, E, Q, D, K), or a variant thereof);
X6 is a hydrophilic amino acid, an amino acid comprising an aromatic ring (e.g., W, or F, or a variant thereof), or an N-methylated amino acid thereof;
X7 is an amino acid comprising an aromatic ring (e.g., W, F, or a variant thereof);
X8 is a hydrophobic amino acid, a hydrophilic amino acid, or an N-methylated amino acid;
X9 is an amino acid comprising an aromatic ring (e.g., W, F or a variant thereof);
X10 is a hydrophilic amino acid (e.g., T, S, N, Q, K, Cit, or a variant thereof);
X11 is a hydrophilic amino acid; and
X12 is C or a variant thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The (cyclic) peptide of any one of claims 1 to 20, wherein
X1 is an amino acid (e.g., D-amino acid);
X2 is F, Y, W, a variant thereof, or an N-methylated amino acid thereof;
X3 is N, Q, Cit, G, Alb, K, A, or a variant thereof;
X4 is G, A, Cit, or a variant thereof (e.g., G substituted with straight or branched C1-5 alkyl, G substituted with C3-7 cycloalkyl, or A substituted with C3-7 cycloalkyl);
X5 is a hydrophilic L-amino acid, wherein the L-amino acid comprises a functional group selected from —NH2—C(O)OH, —NHC(NH)NH2, —NHC(O)NH2, —C(O)NH2, and —NHC(O)CH3;
X6 is a hydrophilic amino acid, F, Y, W, N-methylated amino acid thereof, or a variant thereof, wherein the hydrophilic amino acid comprises a functional group selected from —C(O)OH, C (O) NH2, and —NHC(O)CH3;
X7 is F, W, or a variant thereof;
X8 is G substituted with one or two straight or branched C1-5 alkyl, G substituted with C3-7 cycloalkyl, A substituted with C3-7 cycloalkyl, or a hydrophilic L-amino acid wherein the hydrophilic L-amino acid comprises —NH2, one or more —OH, —C(O)OH, —NHC(NH)NH2, —NHC(O)NH2, —C(O)NH2, or —NHC(O)CH3; or the hydrophilic amino acid comprises a zwitterion;
X9 is F, W, or a variant thereof;
X10 is absent, Q, S, K, Cit, N, T, or a variant thereof (e.g., Q, S, K, Cit, N, or T optionally substituted with straight or branched C1-5 alkyl) or an L-amino acid comprising —NHC(NH)NH2, —NHC(O)NH2, —C(O)NH2, or —NHC(O)CH3;
X11 is absent, E, Q, R, Cit, K, D, or N, or a variant thereof; and
X12 is C or a variant thereof.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The (cyclic) peptide of any one of claims 1 to 21, wherein the peptide has an amino acid sequence according to Formula (I), or a pharmaceutically acceptable salt thereof,
wherein,
X1 is da, df3CON, dkCOpipzaa, dahp, dDab-NH2-Ph3-SO2F, dDap-NH2-Ph3-SO2F, dDap-NH2-Ph4-SO2F, dCit, Aib, G, Norvaline, Norleucine, d4PyCON, or dhAla;
X2 is MeF, Me3Py, MeF3CON, MeF3F, Me4Py, or MeY(Me);
X3 is absent, N, Q, Cit, G, Aib, Hgn, hCit, norCit, LysAc, OrnAc, Ala, or da;
X4 is L, Cbg, Chg, Cba, Cha, Ahx, Dahp, Cit, I, V, Norleucine, or Norvaline;
X5 is Hgl, Hgn, Dab, Dap, DabAc, DapAc, R, hArg, E, or D;
X6 is absent, MeF, MeE, Me3Py, Me4Py, MeF4F, MeF4F, MeF4C, or MeY;
X7 is W1Me, W1Me7Cl, W1Me7N, W, F, 7-AzaTrp, W7Me, W1Et, W1Me7Br, W1Me7OMe, or W1Me6O7Cl;
X8 is V, KCOpipzaa, N, Cit, Qglucamine, hCit, K, KAc, Aib, Alb, DapAc, OrnAc, A, T, alT, Norleucine, Norvaline, Hgl, E, Hgn, Q, I, or L;
X9 is W1Me, W1Me7Cl, W1Me7N, F23dMe, W1Et, W7Me, W, F, or 7-AzaTrp;
X10 is absent, T, Q, S, Hgn, Alpha-methylserine, hSer, hThr, N, OrAc, LysAc, Cit, or hCit;
X11 is absent, E, Hgn, R, hArg, Cit, hCit, Hgl, Orn, D, N, Q, DapAc, OrnAc, DabAc, norCit; and
X12 is C, hCys, CdMe, C3RMe, C3SMe, Selenocysteine, do, or Penicillamine.

### Claim 23 (depends on 18, 19, 20, 21, 22)

The (cyclic) peptide of any one of claims 18-22, wherein
X7 is W1Me or a variant thereof; and
X9 is W1Me or a variant thereof.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The (cyclic) peptide of any one of claims 18-23, wherein
X7 is W1Me, W1MeCl, W1MeBr, Nal1, Nal2, W1Et, 3Bzf, 38zt, F23dC, W1Me7N, or F23dMe;
X8 is V, KCOpipzaa, N, Cit, hCit, KAc, DapAc, OrAc, A, T, alT, Aib, Alb, Qglucamine, Hgl, Q, E, Hgn, or K; and
X8 is V, KCOpipzaa, N, Cit, hCit, KAc, DapAc, OrnAc, A, T, alT, Aib, Alb, Qglucamine, Hgl, Q, E, Hgn, or K; and
X9 is W1Me, Nal1, W1Et, Nal21N, 3Bzf, 3Bzt, Nal18N, F23dMe, or F23dC.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The (cyclic) peptide of any one of claims 1 to 17, wherein the peptide comprises an amino acid sequence according to Formula (I), or a pharmaceutically acceptable salt thereof,
wherein,
X1 is any amino acid,
X2 is an amino acid having an aromatic ring or a variant thereof,
X3 is N,
X4 is a hydrophobic amino acid or a variant thereof;
X5 is a hydrophilic amino acid or a variant thereof;
X6 is a hydrophilic amino acid or amino acid having aromatic ring;
X7 is W or a variant thereof;
X8 is V or hydrophilic amino acid or a variant thereof,
X9 is W or a variant thereof;
X10 is T or a variant thereof;
X11 is a hydrophilic amino acid;
X12 is C or a variant thereof (such as C).

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The (cyclic) peptide of any one of claims 1 to 17, wherein the peptide has an amino acid sequence according to Formula (Ia), or a pharmaceutically acceptable salt thereof,
wherein,
X1 is any amino acid;
X2 is an amino acid having an aromatic ring or a variant thereof;
X3 is N or a variant thereof;
X4 is a hydrophobic amino or a variant thereof,
X5 is a hydrophilic amino acid or a variant thereof;
X6 is a hydrophilic amino acid or amino acid having aromatic ring;
X7 is W or a variant thereof;
X8 is a hydrophilic amino acid or a variant thereof,
X9 is W or a variant thereof; and
X12 is C or a variant thereof.

### Claim 27

A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide consists of a sequence of Formula (I),
or a pharmaceutically acceptable salt thereof,
wherein
each of X1, X2, X3, X4, X5, X6, and X8 is independently an amino acid;
X7 is W1Me or a variant thereof;
X9 is W1Me or a variant thereof;
each of X10 and X11 is independently absent or an amino acid; and
X12 is cysteine (C) or a variant thereof; and,
optionally, a linker that connects the peptide with a payload molecule.

### Claim 28 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The (cyclic) peptide of any one of claims 7-27, wherein the variant of an amino acid is selected from amino acids having one, two or three substituents based on the amino acid, and wherein the substituents are independently selected from halogen, —CN, —NH2, —NH(C1-C3alkyl), —N(C1-C3alkyl)2, oxo, —OH, —CO2H, —CO2—C1-C3alkyl, —C(═O)NH2, —C(═O)NH(C1-C3alkyl), —C(═O)N(C1-C3alkyl)2, —S(═O)2NH2, —S(═O)2NH(C1-C3alkyl), —S(═O)2N(C1-C3alkyl)2, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C6 cycloalkyl, 6-10 membered heterocycloalkyl, and 6-10 membered heteroaryl.

### Claim 29 (depends on 28)

The (cyclic) peptide of claim 28, wherein the variant is selected from amino acids having one or two substituents based on the amino acid, and wherein the substituents are independently selected from halogen, —CN, —NH2, —NH(C1-C3alkyl), —N(C1-C3alkyl)2, oxo, —OH, —CO2H, —CO2—C1-C3alkyl, —C(═O)NH2, —C(═O)NH(C1-C3alkyl), —C(═O)N(C1-C3alkyl)2, and C1-C6 alkyl.

### Claim 30 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The (cyclic) peptide of any one of claims 7-29, wherein the variant is selected from amino acids that have the similar hydrophilicity or hydrophobicity compared to the reference amino acid.

### Claim 31 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The (cyclic) peptide of any one of claims 7-29, wherein the variant is selected from amino acids that have the same functional group as the reference amino acid, and wherein the variant has a different length of a side chain compared to the reference amino acid.

### Claim 32 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The (cyclic) peptide of any one of claims 7-31, wherein the variant has a molecular weight that does not vary for more than 14, 28, 30, 45 or 60 g/mol compared to the reference amino acid.

### Claim 33

A (cyclic) peptide having avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide has an amino acid sequence of Formula (I),
wherein,
X1 is any D- or L-amino acid;
X2 has a structure of
wherein
ring A2 is phenyl or a 6-membered heteroaryl (e.g., heteroaryl having 1 or 2 N);
RX2 is each independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5, —SRa, —S(═O)2Ra, —S(═O)2Ra, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, or heterocycloalkyl is optionally and independently substituted with one or more RXA;
kx2 is 0, 1, 2, or 3;
mx2 is 0, 1, 2, 3 or 4;
RNX2 is H, C1-C6 alkyl, or C1-C6 haloalkyl;
*X1 indicates the point of attachment to X1; and,
*X3 indicates the point of attachment to X3;
X3 has a structure of
wherein
kx3 is 0, 1, 2, or 3;
RNX3 is H, C1-C6alkyl, or C1-C6haloalkyl;
RX3 is H, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl;
*X2 indicates the point of attachment to X2; and,
*X4 indicates the point of attachment to X4;
X4 is a hydrophobic amino acid (e.g., amino acid having 4 or more carbon atoms in a side chain comprising a linear, branched, or cyclic carbon chain), and wherein X4 is optionally N-alkylated by a C1-3 alkyl group;
X5 is a hydrophilic L-amino acid, such as an amino acid having a structure of
wherein:
RNX5 is H, —CN, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl; wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, or heteroalkyl is optionally and independently substituted with one or more RXA;
RXN5 is —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═NR)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl; wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, or heteroalkyl is optionally and independently substituted with one or more RXA;
provided that at least one of RNX5 and RX5 comprises a moiety selected from —OH, —NH2, and —NH— (e.g. —NH—C(═NH)—NH2, —CO—NH2, —NH2, —COOH, —C(OH)—C0-6 alkyl, —NH—CO—C1-6 alkyl);
*X4 indicates the point of attachment to X4; and,
*X6 indicates the point of attachment to X6;
X6 is
wherein
RNX6 is H, C1-C6alkyl, or C1-C6haloalkyl;
RX6 is —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═NRb)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally and independently substituted with one or more RXA;
*X5 indicates the point of attachment to X5; and,
*X7 indicates the point of attachment to X7;
X7 has a structure of
wherein
RNX7 is H, C1-C6alkyl, or C1-C6haloalkyl;
ring A7 is an aryl or heteroaryl;
RX7 is each independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5; —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2-halogen, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, or heterocycloalkyl is optionally and independently substituted with one or more RXA;
kx7 is 0, 1, 2, or 3;
mx7 is 0, 1, 2, 3, 4 or 5;
*X6 indicates the point of attachment to X6; and,
*X8 indicates the point of attachment to X8;
X8 is an L-amino acid with —H on the alpha-amino group;
X9 has a structure of
wherein
RNX9 is H, C1-C6alkyl, or C1-C6haloalkyl;
ring A9 is an aryl or heteroaryl;
RX9 is each independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, or heterocycloalkyl is optionally and independently substituted with one or more RXA;
kx9 is 0, 1, 2, or 3;
mx9 is 0, 1, 2, 3, 4, or 5;
*X8 indicates the point of attachment to X8; and,
*XC indicates the point of attachment to (i) X10 or (i) when X10 and X11 are absent, X12;
X10 is absent or an L-amino acid;
X11 is absent or an L-amino acid; provided that when X10 is absent, then X11 is also absent; and
X12 is an L-amino acid having a reactive thiol group, such as Cys and Cys variants;
each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkyl(cycloalkyl), C1-C6alkyl(heterocycloalkyl), C1-C6alkyl(aryl), or C1-C6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkyl(cycloalkyl), C1-C6alkyl(heterocycloalkyl), C1-C6alkyl(aryl), or C1-C6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkyl(cycloalkyl), C1-C6alkyl(heterocycloalkyl), C1-C6alkyl(aryl), or C1-C6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; and
each R and RXA is independently halogen, —CN, —OH, —OC1-C6alkyl, SF5, —S(═O)C1-C6alkyl, —S(═O)2C1-C6alkyl, —S(═O)2NH2, —S(═O)2-halogen, —S(═O)2NHC1-C6alkyl, —S(═O)2N(C1-C6alkyl)2, —NH2, —NHC1-C6alkyl, —N(C1-C6alkyl)2, —NRbC(═NRb)NRcRd, —NHC(═O)OC1-C6alkyl, —C(═O)C1-C6alkyl, —C(═O)OH, —C(═O)OC1-C6alkyl, —C(═O)NH2, —C(═O)N(C1-C6alkyl) 2, —C(═O)NHC1-C6alkyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl;
optionally, the peptide is linked to a payload molecule via a linker.

### Claim 34 (depends on 33)

The (cyclic) peptide of claim 33, wherein ring A7 is a 6-membered aryl or heteroaryl, or a 9- or 10-membered bicyclic aryl or heteroaryl, wherein the 6-, 9- or 10-membered heteroaryl has one heteroatom selected from N, O, and S.

### Claim 35 (depends on 33, 34)

The (cyclic) peptide of claim 33 or 34, wherein RNX7 is H.

### Claim 36 (depends on 33, 34, 35)

The (cyclic) peptide of any one of claims 33 to 35, wherein each RX7 is independently selected from —CH3, -ethyl, —Cl, and —F, and mx7 is 0, 1, or 2.

### Claim 37 (depends on 33)

The (cyclic) peptide of claim 33, wherein X7 is W1Me, Nal1, Nal2, W1Et, Nal21N, 3Bzf, 3Bzt, Nal15N, Nal14N, Nal24N, Nal28N, F23dMe, F23dC, W1Me7N, or W1Me7Cl.

### Claim 38 (depends on 37)

The (cyclic) peptide of claim 37, wherein X7 is W1Me, F23dMe or W1Me7Cl.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The (cyclic) peptide of any one of claims 33 to 38, wherein X9 is
each RX9 is independently selected from —OH, CN, NH2, C1-C3alkyl, —Cl, —F, —Br, —CONH2, and —SO2F.

### Claim 40 (depends on 33, 34, 35, 36, 37, 38, 39)

The (cyclic) peptide of any one of claims 33 to 39, wherein

### Claim 41 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

The (cyclic) peptide of any one of claims 33 to 40, wherein RX9 is each independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl.

### Claim 42 (depends on 33, 34, 35, 36, 37, 38)

The (cyclic) peptide of any one of claims 33 to 38, wherein X9 is W1Me, W, Nal1, W1Et, Nal21N, 3Bzf, 3Bzt, Nal14N, Nal18N, F23dMe, F23dC, or W1Et.

### Claim 43 (depends on 42)

The (cyclic) peptide of claim 42, wherein X9 is W1Me or F23dMe.

### Claim 44 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The (cyclic) peptide of any one of claims 33 to 43, wherein ring A2 is a 6-membered heteroaryl containing 1 or 2 N.

### Claim 45 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The (cyclic) peptide of any one of claims 33 to 44, wherein RXN5 is C1-C6hydroxyalkyl, C1-6aminoalkyl, —C0-6 alkylene-NH—C(═NH)—NH2, —C0-6 alkylene-CO—NH2, —C0-6 alkylene-COOH, or —NH—CO—C1-6 alkyl.

### Claim 46 (depends on 27, 28, 29, 30, 31, 32, 33)

The (cyclic) peptide of any one of claims 27-33, wherein
X7 is W1Me, W1MeCl, W1MeBr, Nal1, Nal2, W1Et, 3Bzf, 3Bzt, F23dC, W1Me7N, or F23dMe;
X8 is V, KCOpipzaa, Hse, N, Cit, hCit, KAc, DapAc, OrAc, T, alT, Aib, Alb, Qglucamine, Hgl, E, Hgn, MeF, 3Py6NH2, W1Me, A, Q, or K; and
X9 is W1Me, Nal1, W1Et, Nal21N, 3Bzf, 3Bzt, Nal18N, F23dMe, or F23dC.

### Claim 47 (depends on 24, 46)

The (cyclic) peptide of claim 24 or 46, wherein
X7 is W1Me;
X8 is V; and,
X9 is W1Me.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The (cyclic) peptide of any one of claims 1-47, wherein the peptide or the pharmaceutically accepted salt thereof has a cyclic structure, wherein the first amino acid (or X1) is covalently linked to the last amino acid (or X12).

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The (cyclic) peptide of any one of claims 1-48, wherein the peptide or the pharmaceutically accepted salt thereof has a cyclic structure having an amino acid in the first residue X1 and a cysteine residue or a variant thereof, and wherein the amino acid in X1 and the cysteine residue or variant thereof form a covalent bond.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The (cyclic) peptide of any one of claims 1-49, wherein the peptide has a monocyclic structure.

### Claim 51 (depends on 50)

The (cyclic) peptide of claim 50, wherein the amino acid X1 and a cysteine or a variant thereof form a covalent bond.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The (cyclic) peptide of any one of claims 1-51, wherein the peptide has a structure of Formula (I-1),
wherein
R1 is selected from the group consisting of NH2 and OH;
R2 is selected from the group consisting of H or C1-3 alkyl;
R3 is selected from the group consisting of H or C1-3 alkyl;
wherein X1 to X11 have the definitions described in Formula (I).

### Claim 53 (depends on 52)

The (cyclic) peptide of claim 52, or a pharmaceutically acceptable salt thereof, wherein the peptide of Formula (I-1) has a structure of Formula (I-2),

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The (cyclic) peptide of any one of claims 1-53, wherein the peptide or the salt thereof comprises an amino acid sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 1-171, or a sequence with up to 1, 2, 3, 4, or 5 substitutions by a conserved variant compared to any one of the sequences selected from SEQ ID NOs: 1-171.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The (cyclic) peptide of any one of claims 1-54, wherein the peptide or the salt thereof consists of an amino acid sequence selected from SEQ ID NOs: 1-171.

### Claim 56 (depends on 55)

The (cyclic) peptide of claim 55, wherein the peptide consists of an amino acid sequence selected from SEQ ID NOs: 1-122, 159-163, and 165-171, and the peptide has a cyclic structure having a cysteine residue or a variant thereof at the 12th residue, and wherein the amino acid at X1 (e.g., a chloroacetylated amino acid) and the cysteine residue or a variant thereof at the 12th residue form a covalent bond (e.g., by reacting a chloroacetyl group in the amino acid of X1 with the cysteine residue or a variant thereof).

### Claim 57 (depends on 55)

The (cyclic) peptide of claim 55, wherein the peptide consists of an amino acid sequence selected from SEQ ID NOs: 123-149 and 164, and the peptide has a cyclic structure having a cysteine residue or a variant thereof at the 10th residue, and wherein the amino acid at X1 (e.g., a chloroacetylated amino acid) and the cysteine residue or a variant thereof at the 10th residue form a covalent bond.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The (cyclic) peptide of any one of claims 1-57, wherein the peptide has a binding affinity to a human EphA2 of at most 100 nM as determined by Kd in surface plasmon resonance (SPR) analysis.

### Claim 59 (depends on 58)

The (cyclic) peptide of claim 58, wherein the peptide has a binding affinity to a human EphA2 of at most 1 nM as determined by Kd in surface plasmon resonance (SPR) analysis.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The (cyclic) peptide of any one of claims 1-59, wherein the peptide binds to a ligand-binding domain (LBD) domain of the EphA2.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The (cyclic) peptide of any one of claims 1-60, wherein the peptide interacts with a human EphA2 at one or more amino acid residues selected from Asp53, Met55, Asn57, Met59, Met66, Thr101, Arg103, Phe156, Glu157, Arg159, Val161, Val189, and Ala190.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The (cyclic) peptide of any one of claims 1-61, wherein the peptide interacts with a human EphA2 at Asp53 and Glu157.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The (cyclic) peptide of any one of claims 1-62, wherein the peptide has a plasma half-life (Tin) of at least 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 minutes as determined in vitro in human plasma at 37° C.

### Claim 64 (depends on 63)

The (cyclic) peptide of claim 63, wherein the peptide has a plasma half-life (T1/2) of at least 250 minutes as determined in vitro in human plasma at 37° C.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

A (cyclic) peptide of any one of claims 1-64, covalently linked to a linker that connects the peptide to a payload molecule.

### Claim 66 (depends on 65)

The (cyclic) peptide of claim 65, wherein the linker is attached to the peptide via a non-terminal amino acid residue of the peptide.

### Claim 67 (depends on 66)

The (cyclic) peptide of claim 66, wherein the linker is attached to the 5th amino acid residue or X5.

### Claim 68 (depends on 66)

The (cyclic) peptide of claim 66, wherein the linker is attached to the 8th amino acid residue or X8.

### Claim 69 (depends on 66)

The (cyclic) peptide of claim 66, wherein the linker is attached to the 11th amino acid residue or X11.

### Claim 70 (depends on 65, 66, 67, 68, 69)

The (cyclic) peptide of any one of claims 65 to 69, wherein linker is attached to a lysine of the peptide.

### Claim 71 (depends on 65, 66, 67, 68, 69, 70)

The (cyclic) peptide of any one of claims 65 to 70, wherein the linker is attached to the peptide via the N terminus of the peptide.

### Claim 72 (depends on 65, 66, 67, 68, 69, 70)

The (cyclic) peptide of any one of claims 65 to 70, wherein the linker is attached to the peptide via the C terminus of the peptide.

### Claim 73 (depends on 65, 66, 67, 68, 69, 70, 71, 72)

The (cyclic) peptide of any one of claims 65 to 72, wherein the linker is a bond.

### Claim 74 (depends on 65, 66, 67, 68, 69, 70, 71, 72)

The (cyclic) peptide of any one of claims 65 to 72, wherein the linker comprises 3 to 30 intervening atoms between the payload molecule and the peptide.

### Claim 75 (depends on 65, 66, 67, 68, 69, 70, 71, 72)

The (cyclic) peptide of any one of claims 65 to 72, wherein the linker comprises 6 to 18 intervening atoms between the payload molecule and the peptide.

### Claim 76 (depends on 74, 75)

The (cyclic) peptide of claim 74 or 75, wherein the intervening atoms comprise 1 to 6 nitrogen and 0 to 4 oxygen.

### Claim 77 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76)

The (cyclic) peptide of any one of claims 65-72 and 74-76, wherein the linker comprises one or more amino acid residues.

### Claim 78 (depends on 77)

The (cyclic) peptide of claim 77, wherein the linker comprises one or more amino acids chosen from a lysine residue, an alanine residue, or a phenylalanine residue.

### Claim 79 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78)

The (cyclic) peptide of any one of claims 65-72 and 74-78, wherein the linker comprises one or more structures selected from AEEA, AEEP, AEEEP, and AEEEEP.

### Claim 80 (depends on 65, 66, 67, 68, 69, 70, 71, 72)

The (cyclic) peptide of any one of claims 65-72, wherein the linker has a structure of Formula (II-1)
wherein each L is independently —O—, —NRL—, —N(RL)2—, —OP(═O)(ORL)O—, —S—, —S(═O)—, —S(═O)2—, ═CH—, —C(═O)—, —C(═O)O—, —OC(═O)—, —OC(═O)O—, —C(═O)NRL—, —NRLC(═O)—, —OC(═O)NRL—, —NRLC(═O)O—, —NRLC(═O)NRL—, —NRLC(═S)NRL—, —CRL═N—, —N═CRL, —NRLS(═O)2—, —S(═O)2NRL—, —C(═O)NRLS(═O)2—, —S(═O)2NRLC(═O)—, substituted or unsubstituted C3-C15 cycloalkyl, substituted or unsubstituted C1-C12 heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C1-C30 alkylene, substituted or unsubstituted C2-C30 alkenylene, substituted or unsubstituted C2-C30 alkynylene, substituted or unsubstituted C1-C30 heteroalkylene, —(C1-C30 alkylene)-O—, —O—(C1-C30 alkylene)-, —(C1-C30 alkylene)-NRL—, —NRL—(C1-C30 alkylene)-, —(C1-C30 alkylene)-N(RL)2, or —N(RL)2—(C1-C30 alkylene)-; and
each RL is independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C5 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
n is 1 to 20.

### Claim 81 (depends on 80)

The (cyclic) peptide of claim 80, wherein the linker comprises a structure of Formula (II-1a),
wherein each of L1 and L3 is independently —O—, —NRL—, —N(RL)2—, —OP(═O)(ORL)O—, —S—, —S(═O)—, —S(═O)2—, —CH═CH—, ═CH—, —C≡C—, —C(═O)—, —C(═O)O—, —OC(═O)—, —OC(═O)O—, —C(═O)NRL, —NRLC(═O)—, —OC(═O)NRL—, —NRLC(═O)O—, —NRLC(═O)NRL—, —NRLS(═O)2—, —S(═O)2NRL—, —C(═O)NRLS(═O)2—, or —S(═O)2NRLC(═O)—; and
L2 is absent, substituted or unsubstituted C1-C30 alkylene, or substituted or unsubstituted C1-C30 heteroalkylene.

### Claim 82 (depends on 81)

The (cyclic) peptide of claim 81, wherein L1 is —NH—.

### Claim 83 (depends on 81, 82)

The (cyclic) peptide of claim 81 or 82, wherein L2 is substituted or unsubstituted C1-C30 alkylene, or substituted or unsubstituted C1-C30 heteroalkylene.

### Claim 84 (depends on 81, 82)

The (cyclic) peptide of claim 81 or 82, wherein L2 is substituted or unsubstituted C1-C18 alkylene, or substituted or unsubstituted C1-C18 heteroalkylene.

### Claim 85 (depends on 81, 82, 83, 84)

The (cyclic) peptide of any one of claims 81 to 84, wherein L2 is optionally substituted with one or more substituents selected from —OH, —SH, oxo, amino, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 aminoalkyl, —C(═O)ORL—OC(═O)RL, —OC(═O)ORL, —C(═O)N(RL)2, —NRLC(═O)RL, —OC(═O)N(RL)2, and —NRLC(═O)ORL; and the C1-C6 alkyl is further optionally substituted with one or more substituents chosen from —OH, —SH, oxo, amino, C6-C10 aryl, 6- to 10-membered heteroaryl, —C(═O)ORL, —OC(═O)RL, —OC(═O)ORL, —C(═O)N(RL)2, —NRLC(═O)RL, —OC(═O)N(RL)2, and —NRLC(═O)ORL.

### Claim 86 (depends on 81, 82, 83, 84, 85)

The (cyclic) peptide of any one of claims 81 to 85, wherein L3 is —NH—.

### Claim 87 (depends on 81)

The (cyclic) peptide of claim 81, wherein the linker has a structure of

### Claim 88 (depends on 81)

The (cyclic) peptide of claim 81, wherein the linker has a structure of

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The (cyclic) peptide of any one of claims 1-88, wherein the peptide is a peptide of Formula (I) and wherein, when the peptide is bound to the human EphA2, amino acid residue X7 is located less than 10 Å from the Phe156 of the human EphA2.

### Claim 90 (depends on 89)

The (cyclic) peptide of claim 89, wherein amino acid residue X7 is located less than 6 Å from the Phe156.

### Claim 91 (depends on 89)

The (cyclic) peptide of claim 89, wherein amino acid residue X7 is located less than 4 Å from the Phe156.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The (cyclic) peptide of any one of claims 1-91, wherein the peptide is a peptide of Formula (I) and wherein, when the peptide is bound to the human EphA2, amino acid residue X9 is located less than 10 Å from the Phe156 of the human EphA2.

### Claim 93 (depends on 92)

The (cyclic) peptide of claim 92, wherein amino acid residue X9 is located less than 6 Å from the Phe156.

### Claim 94 (depends on 93)

The (cyclic) peptide of claim 93, wherein amino acid residue X9 is located less than 4 Å from the Phe156.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The (cyclic) peptide of any one of claims 1-94, wherein the peptide is a peptide of Formula (I) and wherein, when the peptide is bound to the human EphA2, amino acid residue X8 is located less than 10 Å from the Phe156 of the human EphA2.

### Claim 96 (depends on 89, 90, 91, 92, 93, 94, 95)

The (cyclic) peptide of any one of claims 89 to 95, wherein the human EphA2 comprises a sequence of SEQ ID NO: 276 or SEQ ID NO: 277.

### Claim 97

A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), and competes for binding to a human EphA2 with a peptide that has an amino acid sequence including deletion, substitution, or addition of one or several amino acids in the amino acid of SEQ ID NO: 1:
da-MeF—N-L-Hgl-MeF-W1Me-V-W1Me-T-E-C (SEQ ID NO: 1)
or a pharmaceutically acceptable salt thereof.

### Claim 98

A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide competes for binding to a human EphA2 with a peptide that has a structure of Formula (I), or a pharmaceutically acceptable salt thereof,
wherein,
X1 is an amino acid;
X2 is an amino acid comprising an aromatic ring, an N-methylated amino acid thereof, or a variant thereof;
X3 is a hydrophilic amino acid (e.g. N, Q, Cit, K or a variant thereof), glycine (G), Alanine (A) or a variant thereof (e.g., da, 2-Aminoisobutyric acid (Aib);
X4 is a hydrophobic amino acid (e.g., leucine (L)), a hydrophilic amino acid (e.g., citrulline (Cit), or a variant thereof;
X5 is a hydrophilic amino acid, or a variant thereof;
X6 is a hydrophilic amino acid, an amino acid comprising an aromatic ring, or an N-methylated amino acid thereof;
X7 is an amino acid comprising an aromatic ring (e.g., W, F, or a variant thereof);
X8 is a hydrophobic amino acid, a hydrophilic amino acid, an N-methylated amino acid, or a variant thereof;
X9 is an amino acid comprising an aromatic ring (e.g., W or a variant thereof);
X10 is absent or a hydrophilic amino acid (e.g., Threonine (T) or a variant thereof);
X11 is absent or a hydrophilic amino acid; and
X12 is cysteine (C) or a variant thereof.

### Claim 99

A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide consists of a sequence of Formula (I),
or a pharmaceutically acceptable salt thereof,
wherein
each of X1, X2, X3, X4, X5, X6, and X8 is independently an amino acid;
X7 is W1Me or a variant thereof;
X9 is W1Me or a variant thereof;
each of X10 and X11 is independently absent or an amino acid; and
X12 is cysteine (C) or a variant thereof; and,
wherein the peptide is optionally linked to a payload molecule through a linker.

### Claim 100 (depends on 97, 98, 99)

The (cyclic) peptide of any one of claims 97 to 99, wherein the peptide competes for binding to a human EphA2 at one or more amino acid residues selected from Asp53, Met55, Asn57, Met59, Met66, Thr101, Arg103, Phe156, Glu157, Arg159, Val161, Val189, and Ala190.

### Claim 101 (depends on 100)

The (cyclic) peptide of claim 100, wherein the peptide competes for binding to human EphA2 at one or more amino acid residues selected from Asp53, Phe156, and Glu157.

### Claim 102 (depends on 97, 98, 99, 100, 101)

The (cyclic) peptide of any one of claims 97 to 101, wherein the human EphA2 comprises a sequence of SEQ ID NO: 276 or SEQ ID NO: 277.

### Claim 103 (depends on 1, 102)

A pharmaceutical composition comprising the peptide or salt thereof according to any one of claims 1-102, and a pharmaceutically acceptable excipient or carrier.

### Claim 104

A conjugate comprising the peptide or salt thereof according to any one of the preceding claims and a substance, wherein the substance is selected from the group consisting of: a nucleotide, a small molecule, a medium sized molecule (e.g., with a M.W. of about 1,000-2,500 Da), a large sized molecule (e.g., with a M.W. of >2,500 Da), a polymer compound, a protein, a peptide, a tag, a biological fragment, a carrier including pharmaceutical compound, or a combination thereof.

### Claim 105 (depends on 1, 102, 103, 104)

A method of treating a disease or disorder characterized by overexpression of EphA2, comprising administering to the subject the peptide or salt thereof according to any one of claims 1-102, the conjugate of claim 103, or the pharmaceutical composition of claim 104.

### Claim 106 (depends on 105)

The method of claim 105, wherein the disease or disorder is cancer.

### Claim 107 (depends on 106)

The method of claim 106, wherein the cancer is selected from glioblastoma, prostate cancer, lung cancer, breast cancer, gastric cancer, ovarian cancer, gladder cancer, colon cancer, esophageal cancer, multiple myeloma and fibrosarcoma.

### Claim 108 (depends on 106)

The method of claim 106, wherein the cancer is non-small cell lung carcinomas (NSCLC).

### Claim 109 (depends on 106)

The method of claim 106, wherein the cancer is triple negative breast cancer.

### Claim 110 (depends on 1, 102, 103, 104)

A kit, tester, or composition for determining the expression level of EphA2 in a sample, wherein the kit, tester, or composition comprises the peptide or salt thereof according to any one of claims 1-102, the conjugate of claim 103, or the pharmaceutical composition of claim 104.

### Claim 111 (depends on 110)

The kit, tester, or composition of claim 110, adapted for use in a method of diagnosing disease or disorder characterized by an overexpression or a decreased expression of EphA2.

### Claim 112 (depends on 110, 111)

The kit, tester, or composition of claim 110 or 111, wherein the sample is from a subject having a disease or disorder characterized by an overexpression or a decreased expression of EphA2.

### Claim 113

Use of the peptide or salt thereof according to any one of the preceding claims in the manufacture of a medicament for diagnosing and/or treating a disease or disorder characterized by an overexpression or a decreased expression of EphA2.

### Claim 114

The peptide or salt thereof according to any one of the preceding claims, for use in diagnosing and/or treating a disease or disorder characterized by an overexpression or a decreased expression of EphA2.
